GOG-3082 - Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma Endometrial Adenocarcinoma and Urothelial Carcinoma Based on Acrivon OncoSignature Status
This is a clinical study to test a drug called ACR-368 (also known as Prexasertib) for the treatment of ovarian, endometrial, and urothelial cancer that has returned and is resistant to platinum-based chemotherapy. The study will test ACR-368 on its own and in combination with a low-dose chemotherapy drug called Gemcitabine. Patients will be selected for the study based on the results of a test called OncoSignature (a patient selection tumor biopsy test), which will predict how effective ACR-368 will be for each patient. Patients will be allocated to one of two groups based on their OncoSignature result: Arm 1 for patients with a positive OncoSignature result and Arm 2 for patients with a negative or inconclusive OncoSignature result. In Arm 1, patients with a positive OncoSignature result will receive ACR-368 alone in a Phase 2 study. In Arm 2, patients with a negative or inconclusive OncoSignature result will receive a combination of ACR-368 and low-dose gemcitabine in a Phase 1b study to determine the safe and recommended dose of the combination. A Phase 2 study will then test the combination for effectiveness and safety in each cancer type.
Golf Lab | NYU Langone Health
The Golf Lab at NYU Langone’s Sports Performance Center helps golfers improve their game and avoid injury.
Gout Treatment Center | NYU Langone Health
Experts at NYU Langone’s Gout Treatment Center care for people with gout and other crystal-induced arthritis.
Gout Treatment Center Doctors | NYU Langone Health
Find a doctor at the Gout Treatment Center at NYU Langone.
Government & Community Affairs at NYU Langone Health | NYU Langone Health
NYU Langone Health works with government and community organizations to create healthier communities in the New York metropolitan area.
Grace Y. Ko | NYU Langone Health
Grace Y. Ko, NYU Langone’s executive vice president for development and alumni affairs, is responsible for raising philanthropic support.
Graves’ Disease in Children | NYU Langone Health
Experts at Hassenfeld Children’s Hospital at NYU Langone treat children and adolescents with Graves’ disease, an autoimmune condition.
Group Psychotherapy | NYU Langone Health
Specialists at NYU Langone Psychiatry Associates offer group psychotherapy to help facilitate personal growth and healing.
Growth Plate Injuries in Children | NYU Langone Health
Doctors at Hassenfeld Children’s Hospital at NYU Langone diagnose and treat growth plate injuries in children and adolescents.
GS-US-457-6411: A Phase 2 Double-Blinded Randomized Placebo-Controlled Dose-Ranging Study Evaluating the Efficacy and Safety of GS-5290 in Participants with Moderately to Severely Active Ulcerative Colitis
The goal of this study is to learn if investigational drug tilpisertib fosmecarbil (formerly known as GS-5290) is effective and safe in treating participants with moderate to severe ulcerative colitis. The study will compare participants in different treatment groups treated with tilpisertib fosmecarbil with participants treated with placebo. The primary objective of this study is to demonstrate the efficacy of tilpisertib fosmecarbil, compared to placebo control, in achieving Clinical Response at Week 12.